Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Komal Puranik"'
Autor:
Ruth A. Ettinger, Joseph A. Liberman, Devi Gunasekera, Komal Puranik, Eddie A. James, Arthur R. Thompson, Kathleen P. Pratt
Publikováno v:
Blood Advances, Vol 2, Iss 4, Pp 309-322 (2018)
Abstract: Factor VIII (FVIII)–neutralizing antibodies (inhibitors) are a serious complication in hemophilia A (HA). The peptide FVIII2194-2213 contains an immunodominant HLA-DRA*01-DRB1*01:01 (DRB1*01:01)-restricted epitope recognized by CD4+ T-eff
Externí odkaz:
https://doaj.org/article/8cdfc0df3f83466e80e9f6064c811ebe
Autor:
Jasper C Lin, Ruth A Ettinger, Jason T Schuman, Ai-Hong Zhang, Muhammad Wamiq-Adhami, Phuong-Cac T Nguyen, Shelley M Nakaya-Fletcher, Komal Puranik, Arthur R Thompson, Kathleen P Pratt
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0116577 (2015)
The development of neutralizing anti-factor VIII (FVIII) antibodies complicates the treatment of many hemophilia A patients. The C-terminal C2 domain is a particularly antigenic FVIII region. A crystal structure of recombinant FVIII-C2 bound to an Fa
Externí odkaz:
https://doaj.org/article/9f01ce1acfea4daca262cfb00998c208
Autor:
Muhammad Wamiq-Adhami, Arthur R. Thompson, Jason T. Schuman, Jasper C. Lin, Phuong-Cac T. Nguyen, Kathleen P. Pratt, Ruth A. Ettinger, Ai-Hong Zhang, Shelley M. Nakaya-Fletcher, Komal Puranik
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 1, p e0116577 (2015)
PLoS ONE, Vol 10, Iss 1, p e0116577 (2015)
The development of neutralizing anti-factor VIII (FVIII) antibodies complicates the treatment of many hemophilia A patients. The C-terminal C2 domain is a particularly antigenic FVIII region. A crystal structure of recombinant FVIII-C2 bound to an Fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da765772ef34f264c218941385329158
http://europepmc.org/articles/PMC4304825
http://europepmc.org/articles/PMC4304825
Publikováno v:
The Journal of Immunology. 190:43.46-43.46
Hemophilia A patients lack functional factor VIII (FVIII), which is essential for normal blood clotting. Approximately 1 in 4 patients receiving replacement therapy by infusions of FVIII develop neutralizing antibodies that can cause serious bleeds.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8ae7cf52e2eb6f289c2a309d772171a
https://doi.org/10.4049/jimmunol.190.supp.43.46
https://doi.org/10.4049/jimmunol.190.supp.43.46
Autor:
Shelley S. Cole, Eddie A. James, Kathleen P. Pratt, Ruth A. Ettinger, Komal Puranik, Dana C. Matthews, Melinda S. Epstein, Tom E. Howard, Richard J. Hughes, Joseph A. Liberman
Publikováno v:
Blood. 120:39-39
Abstract 39 Neutralizing anti-factor VIII (FVIII) antibodies, or “inhibitors”, interfere with FVIII pro-coagulant activity, and persistent inhibitors can result in significant morbidity and mortality in hemophilia A (HA) patients and in individua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ece415e2c957f2577ad443184b1c045b
https://doi.org/10.1182/blood.v120.21.39.39
https://doi.org/10.1182/blood.v120.21.39.39